Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Pulmonary/Rheumatology Division Sees Management Shakeup

Executive Summary

Deputy Director for Safety Sally Seymour will become interim director of US FDA's Pulmonary, Allergy and Rheumatology Products Division following departure of  division's top two managers, Badrul Chowdhury and Lydia Gilbert McClain.

You may also be interested in...



US FDA Hiring For Senior Staff Vacancies Boosted By Cures Act, Pilot Program – Gottlieb

Recent departures are 'business as usual' at the agency, Commissioner says. 

New OND Director Could Be Hired Within Six Months, Woodcock Says

US FDA's Office of New Drugs has been without a permanent director for more than a year as it undergoes a significant restructuring.

More US FDA Departures: ODE II Director Rosebraugh, GI Division Director Griebel to Retire

FDA will have three leadership positions vacant in the Office of Drug Evaluation II when Curtis Rosebraugh leaves at the end of the month. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel